Compounds that Prevent Age-Related Diseases by Evolutionary Conserved Mechanisms

Brief Description:
These are compounds that increase lifespan in yeast and may lead to the development of drugs effective in treating age-related diseases.

The materials which have lifespan-enhancing characteristics as identified by large scale screening may lead to the development of drugs for age-related diseases in humans, such as diabetes, cancers, and neurodegenerative diseases, including Parkinson’s and Alzheimer’s diseases.  The compounds should be applicable to diseases related to oxidation damage.  The compounds may also be useful for radiation protection, since the screening was designed to counteract nicotinamide, which is a radiation sensitizer as well as life-span reducer.

The compounds were identified in large scale automated screening of a library of over 100,000 compounds, using an assay on lifespan which can be completed in 2 to 3 days.  Any variations of these compounds can also be evaluated using this assay.  Aging research has been slowed by the lack of a rapid assay.  Our technology provides the only cell-based lifespan assay that lends itself to high-throughput screening.

Technology Status:
The assay by which these compound were discovered has been tested relative to the SIR2 gene which is known to have a role in aging.  The result strongly supports the initiation of a program of drug discovery.  These compounds were the identified in a chemical screening of 130,000 compounds.  A lead compound that extends life under this assay is now undergoing validation testing.  Additional collaborations in drug discovery are being explored.

URV Reference Number: 1-11027-08013
Patent Information:
For Information, Contact:
John Fahnervihtelic
Senior Licensing Manager
University of Rochester
David Goldfarb